Experimental cancer drug trial halted early

NCT ID NCT02597036

Terminated Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested an experimental drug called LY3127804, alone or combined with another cancer drug (ramucirumab), in 62 people with advanced solid tumors. The main goal was to find a safe dose. The study was terminated early, and researchers could not determine a maximum safe dose because no dose-limiting side effects were reported.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3127804 (an experimental antibody) and ramucirumab (a cancer drug)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors.
What could go wrong: This was a very early (Phase 1) study that was terminated before completion. No maximum safe dose was determined, and it is unclear if the drug will be effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Brussels, 1000, Belgium
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Villejuif, 94805, France
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Barcelona, 08035, Spain
SMO Sarah Cannon Research Inst.

Nashville, Tennessee, 37203, United States
Tennessee Oncology PLLC

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.